Stock Analysis, Dividends, Split History

FRSH / Papa Murphy's Holdings, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)94.21
Enterprise Value ($M)188.87
Book Value ($M)97.56
Book Value / Share5.73
Price / Book0.98
NCAV ($M)-141.81
NCAV / Share-8.33
Price / NCAV-0.58
Share Statistics
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 16,971,461
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.00
Return on Assets (ROA)-0.00
Return on Equity (ROE)-0.00
Balance Sheet (mrq) ($M)
Quick Ratio0.31
Current Ratio0.34
Income Statement (mra) ($M)
Royalty Revenue37,552,000.00
Other Sales Revenue Net2,021,000.00
Revenue From Franchisor Owned Outlets76,868,000.00
Franchise Revenue2,220,000.00
Sales Revenue Net118,661,000.00
Operating Income-14.27
Net Income-0.01
Earnings Per Share Diluted0.00
Earnings Per Share Basic0.00
Cash Flow Statement (mra) ($M)
Cash From Operations15.54
Cash from Investing-1.65
Cash from Financing-1.65
Identifiers and Descriptors
Central Index Key (CIK)1592379
Related CUSIPS
698814900 698814950

Split History

Stock splits are used by Papa Murphy's Holdings, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Strong U.S. Consumer Spending Seen Boosting Q2 Retail Results

2018-08-14 seekingalpha
In the U.S. retail landscape, the strength seen in consumer spending continued into the second quarter of 2018. In fact, analysts polled by Thomson Reuters are becoming more bullish on consumer spending, as retailers get ready to report their earnings for Q2 2018. (91-1)

Cheesecake Factory (CAKE) Misses on Q2 Earnings, Trims View

2018-08-01 zacks
The Cheesecake Factory Inc.’s (CAKE - Free Report) reported second-quarter 2018 results, wherein earnings missed the Zacks Consensus Estimate for the two consecutive quarters. The bottom line also declined sharply from the prior-year quarter number. Following the quarterly results, shares of the company decreased 9% in after-hours trading on Jul 31. (4-0)

BJ's Restaurants (BJRI) Q2 Earnings, Revenues Top Estimates

2018-07-27 zacks
BJ’s Restaurants, Inc.’s (BJRI - Free Report) top and bottom lines both surpassed the Zacks Consensus Estimate in the second quarter of 2018. Adjusted earnings of 79 cents surpassed the consensus estimate of 64 cents by 23.4%. Earnings surged 61.2% year over year favored by improved comps and restaurant operating margins. (1-0)

Domino's (DPZ) Q2 Earnings Top, Stock Down on Sales Miss

2018-07-20 zacks
Domino's Pizza, Inc. (DPZ - Free Report) reported mixed quarterly numbers for second-quarter 2018, wherein earnings surpassed the Zacks Consensus Estimate but revenues missed the same. Following the results, investors took apprehensive stance resulting in share price decline of 2.4% yesterday. Lower-than-expected revenues and same-store sales growth led to the downside. However, in a year’s time, the stock has rallied 29.

6 Top-Ranked Stocks to Buy as Retail Sales Remain Robust

2018-07-17 zacks
In June, retail sales increased substantially, marking the fifth straight month of gains. Though autos and gasoline led the charge, gains were largely broad-based. It seems that a combination of tax cuts and consistent job additions are supporting growth in household purchases. (3-0)

CUSIP: 698814100